$515 Million is the total value of Integral Health Asset Management, LLC's 65 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GH | Buy | GUARDANT HEALTH INC | $24,224,000 | +55.9% | 450,000 | +16.8% | 4.71% | +47.2% |
| New | CYTOKINETICS INCcall | $22,108,000 | – | 456,300 | +100.0% | 4.30% | – | |
| BAX | New | BAXTER INTL INC | $16,158,000 | – | 300,000 | +100.0% | 3.14% | – |
| MRK | Buy | MERCK & CO INC | $15,932,000 | +67.4% | 185,000 | +77.3% | 3.10% | +58.2% |
| NVST | Buy | ENVISTA HOLDINGS CORPORATION | $14,436,000 | -3.0% | 440,000 | +13.9% | 2.80% | -8.4% |
| CRSP | Buy | CRISPR THERAPEUTICS AGnamen akt | $14,377,000 | +195.7% | 220,000 | +175.0% | 2.79% | +179.3% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $14,011,000 | +104.5% | 70,000 | +49.0% | 2.72% | +93.2% |
| BSX | New | BOSTON SCIENTIFIC CORP | $13,556,000 | – | 350,000 | +100.0% | 2.63% | – |
| RLAY | Buy | RELAY THERAPEUTICS INC | $13,422,000 | +83.7% | 600,000 | +37.5% | 2.61% | +73.5% |
| BIIB | New | BIOGEN INC | $13,350,000 | – | 50,000 | +100.0% | 2.59% | – |
| CAH | New | CARDINAL HEALTH INC | $13,336,000 | – | 200,000 | +100.0% | 2.59% | – |
| ZNTL | Buy | ZENTALIS PHARMACEUTICALS INC | $11,913,000 | +24.6% | 550,000 | +61.6% | 2.31% | +17.6% |
| PRGO | Buy | PERRIGO CO PLC | $11,411,000 | +54.0% | 320,000 | +75.2% | 2.22% | +45.5% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $9,559,000 | – | 90,000 | +100.0% | 1.86% | – |
| PTCT | Buy | PTC THERAPEUTICS INC | $8,183,000 | +95.2% | 163,000 | +55.7% | 1.59% | +84.5% |
| QURE | Buy | UNIQURE NV | $8,123,000 | +23.4% | 433,000 | +22.6% | 1.58% | +16.5% |
| DHR | New | DANAHER CORPORATION | $7,749,000 | – | 30,000 | +100.0% | 1.50% | – |
| UNH | New | UNITEDHEALTH GROUP INC | $7,576,000 | – | 15,000 | +100.0% | 1.47% | – |
| INSP | New | INSPIRE MED SYS INC | $7,095,000 | – | 40,000 | +100.0% | 1.38% | – |
| NTLA | Buy | INTELLIA THERAPEUTICS INC | $6,995,000 | +61.8% | 125,000 | +49.7% | 1.36% | +52.9% |
| KURA | Buy | KURA ONCOLOGY INC | $6,830,000 | -19.2% | 500,000 | +8.4% | 1.33% | -23.7% |
| ISEE | New | IVERIC BIO INC | $6,728,000 | – | 375,000 | +100.0% | 1.31% | – |
| KRYS | Buy | KRYSTAL BIOTECH INC | $6,273,000 | +83.1% | 90,000 | +72.5% | 1.22% | +72.9% |
| DVA | Buy | DAVITA INC | $6,208,000 | +48.8% | 75,000 | +43.7% | 1.21% | +40.6% |
| PODD | New | INSULET CORP | $5,735,000 | – | 25,000 | +100.0% | 1.11% | – |
| ILMN | New | ILLUMINA INC | $5,724,000 | – | 30,000 | +100.0% | 1.11% | – |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $5,352,000 | +34.1% | 340,000 | +18.9% | 1.04% | +26.7% |
| MRTX | New | MIRATI THERAPEUTICS INC | $4,889,000 | – | 70,000 | +100.0% | 0.95% | – |
| EXAS | New | EXACT SCIENCES CORP | $4,874,000 | – | 150,000 | +100.0% | 0.95% | – |
| NVRO | Buy | NEVRO CORP | $4,660,000 | +35.8% | 100,000 | +27.8% | 0.90% | +28.2% |
| RVNC | New | REVANCE THERAPEUTICS INC | $4,050,000 | – | 150,000 | +100.0% | 0.79% | – |
| ITOS | Buy | ITEOS THERAPEUTICS INC | $3,715,000 | +15.2% | 195,000 | +24.6% | 0.72% | +8.9% |
| GOSS | New | GOSSAMER BIO INC | $3,594,000 | – | 300,000 | +100.0% | 0.70% | – |
| DNLI | New | DENALI THERAPEUTICS INC | $3,529,000 | – | 115,000 | +100.0% | 0.69% | – |
| New | VENTYX BIOSCIENCES INC | $3,491,000 | – | 100,000 | +100.0% | 0.68% | – | |
| SIBN | Buy | SI-BONE INC | $3,492,000 | +68.1% | 200,000 | +27.1% | 0.68% | +58.8% |
| LFST | Buy | LIFESTANCE HEALTH GROUP INC | $3,476,000 | +66.4% | 525,000 | +39.7% | 0.68% | +57.0% |
| AMED | New | AMEDISYS INC | $3,194,000 | – | 33,000 | +100.0% | 0.62% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $2,828,000 | – | 100,000 | +100.0% | 0.55% | – |
| DSGN | New | DESIGN THERAPEUTICS INC | $2,090,000 | – | 125,000 | +100.0% | 0.41% | – |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $1,857,000 | – | 30,000 | +100.0% | 0.36% | – |
| Buy | CINCOR PHARMA INC | $1,641,000 | +108.5% | 50,000 | +19.8% | 0.32% | +96.9% | |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $532,000 | +35.0% | 377,000 | +14.8% | 0.10% | +27.2% |
| LBPH | Buy | LONGBOARD PHARMACEUTICALS IN | $409,000 | +131.1% | 110,000 | +91.9% | 0.08% | +119.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 15 | Q3 2023 | 4.7% |
| SAGE THERAPEUTICS INC | 15 | Q2 2023 | 5.0% |
| BIOMARIN PHARMACEUTICAL INC | 15 | Q2 2023 | 4.1% |
| ENVISTA HOLDINGS CORPORATION | 14 | Q3 2023 | 4.0% |
| AKERO THERAPEUTICS INC | 14 | Q3 2023 | 1.5% |
| REVVITY INC | 13 | Q3 2023 | 4.2% |
| BLUEPRINT MEDICINES CORP | 13 | Q3 2023 | 3.3% |
| PTC THERAPEUTICS INC | 13 | Q2 2023 | 1.7% |
| ELEVANCE HEALTH INC | 12 | Q3 2023 | 6.7% |
| NEVRO CORP | 12 | Q4 2022 | 4.5% |
View Integral Health Asset Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-12 |
| 13F-HR | 2022-02-02 |
| 13F-HR | 2021-11-12 |
View Integral Health Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.